Mechanisms of immune evasion and current status of checkpoint inhibitors in non‐small cell lung cancer

• Published in: Cancer medicine (Malden, MA) Vol. 5; no. 9; pp. 2567 - 2578
• Main Authors: Qin, Angel, Coffey, David G., Warren, Edus H., Ramnath, Nithya
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.09.2016; John Wiley and Sons Inc
• Subjects: Animals; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Antigen presentation; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; B7-H1 Antigen - antagonists & inhibitors; Cancer Biology; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - immunology; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Chemotherapy; Cytokines; Cytotoxicity; Determinants of response; Humans; Immune checkpoint; Immune evasion; Immune system; Immune System - cytology; Immune System - drug effects; Immune System - immunology; Immune System - metabolism; Immune Tolerance - drug effects; Immunogenicity; Immunologic Factors - pharmacology; Immunologic Factors - therapeutic use; Immunotherapy; Kidney cancer; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - immunology; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Lymphocytes; Melanoma; Metastasis; Molecular Targeted Therapy; Mutation; Non-small cell lung carcinoma; non‐small cell lung cancer; PD-L1 protein; PD‐1; PD‐L1; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Proteins; Review; T-Lymphocyte Subsets - drug effects; T-Lymphocyte Subsets - immunology; T-Lymphocyte Subsets - metabolism; Tumor Escape - drug effects; Tumor Microenvironment - immunology; Tumor necrosis factor-TNF; Vaccines; non-small cell lung cancer; PD-L1; Determinants of response; immune evasion; PD-1

In the past several years, immunotherapy has emerged as a viable treatment option for patients with advanced non‐small cell lung cancer (NSCLC) without actionable driver mutations that have progressed on standard chemotherapy. We are also beginning to understand the methods of immune evasion employe...